5 Stocks Delivering Massive Returns

2. Legend Biotech Corp. (NASDAQ:LEGN)

Legend Biotech snapped a four-day losing streak on Tuesday, jumping 42.22 percent to close at $36.28 apiece following the strong first phase results of its cancer treatment candidate, which saw as much as a 100 percent response rate in enrolled patients.

In an updated report, Legend Biotech Corp. (NASDAQ:LEGN) said that all six patients enrolled in the study to test the efficacy of LB2501 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma fully responded to the higher dose level of the treatment, while five achieved a complete response, which means that no detectable signs of cancer remained.

LB2501 is designed to infuse CAR-T cells directly into the patient’s body via a single IV. It is expected to treat faster and be less expensive than the traditional CAR-T therapies, which require a patient’s cells to be collected first and engineered in laboratories and infused back weeks later.

Legend Biotech Corp. (NASDAQ:LEGN) also said that the therapy candidate showed no serious adverse effects or deaths.

The company is scheduled to present additional data at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, on June 11 to 14.

“The upcoming presentation of Phase 1 LB2501 data in patients with B-cell malignancies represents an important step in advancing in vivo CAR-T approaches,” Legend Biotech Corp. (NASDAQ:LEGN) CEO Ying Huang said.

“By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies. LB2501 is built on the TaVec platform, which is a proprietary lentiviral vector engineered to enhance T-cell specificity, transduction efficiency, and safety, while restricting transduction of non-T cells.”